Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...
Stocktwits on MSN3d
Moderna Stock Sinks To Over 5-Year Low On $1B Sales Guidance Cut: Retail’s ShakenShares of Moderna, Inc. plunged over 20% on Monday to their lowest levels since mid-April 2020 and were on course to mark ...
Moderna slashed its 2025 revenue projection by $1bn on Monday, citing reduced demand for its Covid-19 and respiratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback